Literature DB >> 16519507

Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.

Tong Li1, Hemant K Paudel.   

Abstract

Phosphorylation of tau on S(396) was suggested to be a key step in the development of neurofibrillary pathology in Alzheimer's disease brain [Bramblett, G. T., Goedert, M., Jacks, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V. M.-Y. (1993) Neuron 10, 1089-1099]. GSK3beta phosphorylates Ser(396) of tau in the brain by a mechanism which is not clear. In this study, when HEK-293 cells were cotransfected with tau and GSK3beta, GSK3beta co-immunoprecipitated with tau and phosphorylated tau on S(202), T(231), S(396), and S(400) but not on S(262), S(235), and S(404). Blocking phosphorylation on T(231), S(235), S(396), S(400), or S(404) did not prevent the subsequent phosphorylation on S(202) by GSK3beta. These data suggest that GSK3beta directly phosphorylates tau on S(202) (without requiring prephosphorylation). However, preventing phosphorylation on S(235), S(400), and S(404) prevented GSK3beta-dependent phosphorylation of T(231), S(396), and S(400), respectively. This indicates that phosphorylation of T(231), S(396), and S(400) by GSK3beta depends on a previous phosphorylation of S(235), S(400), and S(404), respectively. To examine S(396) phosphorylation, we analyzed phosphorylation of S(396), S(400), and S(404). Blocking phosphorylation of S(404) prevented the subsequent GSK3beta-dependent phosphorylation of both S(400) and S(396). When phosphorylation of S(404) was allowed but S(400) blocked, GSK3beta failed to phosphorylate S(396). Thus, GSK3beta phosphorylates S(396) by a two-step mechanism. In the first step, GSK3beta phosphorylates S(400) of previously S(404)-phosphorylated tau. This event primes tau for second-step phosphorylation of S(396) by GSK3beta. We conclude that GSK3beta phosphorylates tau directly at S(202) but requires the previous phosphorylation on S(235) to phosphorylate T(231). Phosphorylation of S(396), on the other hand, occurs sequentially. Once a priming kinase phosphorylates S(404), GSK3beta sequentially phosphorylates S(400) and then S(396).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16519507     DOI: 10.1021/bi051634r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  43 in total

Review 1.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

2.  Generation of induced pluripotent stem cells with high efficiency from human embryonic renal cortical cells.

Authors:  Ling Yao; Ruifang Chen; Pu Wang; Qi Zhang; Hailiang Tang; Huaping Sun
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E.

Authors:  Arnaud Leroy; Isabelle Landrieu; Isabelle Huvent; Dominique Legrand; Bernadette Codeville; Jean-Michel Wieruszeski; Guy Lippens
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

4.  Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Authors:  Justin V Louis; Ellen Martens; Peter Borghgraef; Caroline Lambrecht; Ward Sents; Sari Longin; Karen Zwaenepoel; Robert Pijnenborg; Isabelle Landrieu; Guy Lippens; Birgit Ledermann; Jürgen Götz; Fred Van Leuven; Jozef Goris; Veerle Janssens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

5.  Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.

Authors:  Yifan Lu; Tong Li; Hamid Y Qureshi; Dong Han; Hemant K Paudel
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

6.  Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats.

Authors:  Peng Liu; Li-Bo Zou; Li-Hua Wang; Qing Jiao; Tian-Yan Chi; Xue-Fei Ji; Ge Jin
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

7.  Developmental Pathogenicity of 4-Repeat Human Tau Is Lost with the P301L Mutation in Genetically Matched Tau-Transgenic Mice.

Authors:  Julia E Gamache; Lisa Kemper; Elizabeth Steuer; Kailee Leinonen-Wright; Jessica M Choquette; Chris Hlynialuk; Kellie Benzow; Keith A Vossel; Weiming Xia; Michael D Koob; Karen H Ashe
Journal:  J Neurosci       Date:  2019-11-04       Impact factor: 6.167

8.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 9.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Determination of the Best Concentration of Streptozotocin to Create a Diabetic Brain Using Histological Techniques.

Authors:  Marzieh Dehghan-Shasaltaneh; Nasser Naghdi; Samira Choopani; Leila Alizadeh; Bahram Bolouri; Ali Masoudi-Nejad; Gholam Hossein Riazi
Journal:  J Mol Neurosci       Date:  2016-01-20       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.